A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001 + STK-009) in Subjects With Relapsed or Refractory CD19+ Hematologic Malignancies (Leukemia)
Sponsor: |
Synthekine, Inc. |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAU3113 |
U.S. Govt. ID: |
NCT05665062 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The purpose of this study is to find the highest dose of STK-009 that is safe in combination with a dose of SYNCAR-001 and to learn what side effects are experienced in people with certain lymphomas or leukemias. This study will also evaluate how much SYNCAR-001 and STK-009 is in your blood at various times, whether your immune system becomes activated, whether your body produces antibodies (proteins produced by your immune system) against SYNCAR-001 and/or STK-009, and the effects of SYNCAR-001 + STK-009 on your cancer.
This study is closed
Investigator
Ran Reshef, MD
Are you at least 18 years old? |
Yes |
No |
Are you able to give informed consent? |
Yes |
No |